Full-Time

Associate Director of Oncology Pipeline Strategy

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Genetic testing and diagnostics solutions

Biotechnology
Healthcare

Compensation Overview

$133.6k - $192kAnnually

Senior

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Market Research
Requirements
  • Bachelor’s degree required; MBA or PhD preferred.
  • Strong experience in GI oncology markets; expertise in upstream marketing is a plus.
  • 5+ years of experience in product marketing or market analytics within the pharmaceutical or biotech industry.
  • Proven experience managing KOL relationships.
  • Knowledge of oncology molecular testing and biomarkers is strongly preferred.
Responsibilities
  • Lead commercial strategy for GI cancers, collaborating with cross-functional teams to develop and execute strategic plans that drive product adoption across stakeholders (e.g., academic and community oncology).
  • Serve as a critical member of clinical pipeline teams to define and prioritize indications, creating a roadmap to address evidence gaps.
  • Maintain in-depth knowledge of GI cancers by integrating real-time customer feedback, market intelligence, publications, and data presentations.
  • Partner with Medical Affairs and commercial marketing to define value propositions and messaging frameworks for targeted cancer types, ensuring alignment with clinical evidence and market needs.
  • Provide insights to optimize the success of Signatera in GI oncology.
  • Collaborate with Market Access teams to secure reimbursement for non-covered indications, contributing to submissions for Medicare/MolDx and commercial payers.
  • Develop KOL engagement strategies, working closely with marketing and medical teams to build strong relationships and advocacy.
  • Co-develop and execute advisory boards and market research initiatives in collaboration with Medical Affairs.
  • Present strategic plans and progress to executive leadership on a regular basis.

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care through precise genetic insights.

Company Stage

IPO

Total Funding

$149.9M

Headquarters

Austin, Texas

Founded

2004

Growth & Insights
Headcount

6 month growth

8%

1 year growth

24%

2 year growth

61%
Simplify Jobs

Simplify's Take

What believers are saying

  • Natera's continuous innovation, such as the launch of the Prospera Heart test with DQS, demonstrates its commitment to improving patient outcomes and maintaining market leadership.
  • The company's diverse product offerings across oncology, transplant health, and women's health provide multiple revenue streams and reduce dependency on a single market.
  • Significant investments from entities like Massachusetts Financial Services Co. MA indicate strong financial backing and confidence in Natera's growth potential.

What critics are saying

  • Allegations of deceptive sales and billing practices could damage Natera's reputation and lead to legal and financial repercussions.
  • The highly competitive nature of the genetic testing market requires constant innovation and differentiation to maintain market share.

What makes Natera unique

  • Natera's focus on cell-free DNA (cfDNA) technology for a wide range of applications, from oncology to prenatal screening, sets it apart from competitors who may specialize in only one area.
  • The introduction of unique features like the Donor Quantity Score (DQS) for transplant rejection detection enhances the accuracy and reliability of their tests, distinguishing them from other genetic testing companies.
  • Natera's extensive portfolio of over 200 peer-reviewed publications underscores its commitment to scientific validation and credibility, which is a significant competitive advantage.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks